Abstract: Methods, apparatus, and systems to dynamically schedule a workload to among compute blocks based on temperature are disclosed. An apparatus to schedule a workload to at least one of a plurality of compute blocks based on temperature includes a prediction engine to determine (i) a first predicted temperature of a first compute block of the plurality of compute blocks and (ii) a second predicted temperature of a second compute block of the plurality of compute blocks. The apparatus also includes a selector to select between the first compute block and the second compute block for assignment of the workload. The selection is based on which of the first and second predicted temperatures is lower. The apparatus further includes a workload scheduler to assign the workload to the selected one of the first or second compute blocks.

Abstract: The present disclosure relates to a blind fastener and a method of installation thereof. The blind fastener comprises a sleeve and a mandrel. The sleeve comprises a first sleeve end, a second sleeve end, and a cavity extending from the first sleeve end to the second sleeve end. The mandrel is configured to be at least partially received by the cavity of the sleeve. The mandrel comprises a first mandrel end disposed adjacent to the first sleeve end and comprising an enlarged portion having a diameter greater than a diameter of the cavity, a second mandrel end comprising a pull region, and a shank region extending intermediate the first mandrel end and the second mandrel end. The pull region comprises an axial length no greater than four times a diameter of the shank region and is configured to be engaged by an installation tool.

Abstract: A UE communicates with a network gateway to access a provisioning device via a provisioning network. The provisioning device uses identification data of the UE to authenticate the UE for a primary network, and provides primary network configuration data to the UE. Using the primary network configuration data, the UE communicates with the network gateway to access the primary network. The primary network configuration data can include data to enable the UE to establish communications with one or more private networks accessible via the primary network.

Abstract: Disclosed are systems and methods that automatically classify, segment, and parse content data using artificial intelligence and natural language processing technology, and generate graphical user interfaces that allow end users to dynamically filter content data for display. The systems processes volumes of content data to identify interrogative data, content sources that generated the interrogative data, and subject identifiers relating to the content data. The system generates graphical user interfaces that allow end users to effectively filter the data by choosing between layouts that display one or more of the various categories of data, including the interrogative data, content source identifiers, and/or subject identifiers.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A bearing module that supports adjacent ends of coaxial shafts, includes an outer ring having first and second axially adjacent raceways and first and second flanges located at the respective ends. A first group of rolling elements rolls on the first raceway, and a second group of rolling elements rolls on the second raceway. A first cage retains the first group of rolling elements circumferentially spaced apart from one another, and a second cage retains the second group of rolling elements. An axial bearing is retained axially between the first and second groups of rolling elements, and has axial bearing rolling elements that are configured for rolling contact with (a) facing axial side raceways on first and second inner rings supported respectively on the first and second groups of rolling elements, (b) the adjacent ends of the two coaxial shafts, or (c) integral washers of the axial bearing.

Abstract: The present disclosure relates to reduced sugar content milk chocolate confection and confectionery products comprising at least one rare sugar, such as allulose, methods of making the same wherein the confections and confectionery products have desirable rheological properties and organoleptic properties and stable viscosity over time. The present disclosure also relates to preventing thickening of reduced sugar content milk chocolate confections comprising at least one rare sugar, such as allulose, during manufacturing, and maintaining stable viscosity over time.

Abstract: Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

Abstract: A capped bisphenol polyether oligomer including a reactive end group, wherein the capped bisphenol polyether oligomer further includes a repeating unit derived from: a bisphenol monomer, a benzylic dihalide, a tertiary cycloalkyl dihalide, or a combination thereof; and optionally, the capped bisphenol polyether oligomer further includes a branching agent.

Abstract: A chair with a transom, a seat support, a back portion, and a combined rock and recline mechanism. The combined rock and recline mechanism has front and rear rocking arrangements configured to enable the seat support and back portion to together rock generally forward and rearward from a neutral position relative to the transom, and a recline arrangement that is configured such that the seat support is in a first at-rest position relative to the back portion when the back portion is in an upright position, and such that reclining the back portion rearwardly from the upright position toward a reclined position moves the seat support upward and rearward from the first at-rest position.

Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.

Abstract: A composition includes specific amounts of a copolycarbonate and a roughening agent. The copolycarbonate contains first carbonate units derived from a first bisphenol monomer such that a homopolycarbonate of the first bisphenol monomer has a glass transition temperature less than 155° C., and second carbonate units derived from a second bisphenol monomer such that a homopolycarbonate of the second bisphenol monomer has a glass transition temperature of 155° C. or higher. The roughening agent includes a particulate crosslinked polymethylsilsesquioxane having a median equivalent spherical diameter greater than 5 micrometers and less than or equal to 10 micrometers.

Abstract: In one example in accordance with the present disclosure, a fluidic die is described. The fluidic die includes a substrate and fluid actuators, the fluid actuators being disposed on the substrate. The fluidic die also includes a bond pad region defined on the substrate. The bond pad region includes a high aspect ratio power delivery bond pad with multiple bonding sites and a high aspect ratio power return bond pad with multiple bonding sites.

Abstract: The suspension system disclosed may be used to provide anti-gravity or pro-gravity affects to aid in exercise and rehabilitation. The system includes a frame assembly which supports an elastic cord. The elastic cord supports a portion of the weight of the user and exerts upward or downward pressure on the user to reduce or enhance the user's weight. The elastic is configured to equalize the forces on the system and permit free movement of the user while reducing or enhancing the user's weight. The system may be used by itself or with a number of different exercises and equipment.

Abstract: Systems and methods for ensuring medical diagnostic test integrity are disclosed. In particular, systems and methods herein can be used to ensure compliance with testing procedures. Some embodiments provide systems and methods for verifying test results. According to some embodiments, test results can be non-human-readable results that can be interpreted by a computing system.

Abstract: An adjustable spinal stabilization system for maintaining preselected spacing and movement between adjacent vertebrae in a spinal column and for providing overall stability thereto. The system includes at least one interlaminar member positioned in the spaces intermediate a first vertebra and the vertebrae positioned immediately above or immediately below and adjacent to the first vertebra. The interlaminar member is operatively connected to an adjustable support structure and cooperates therewith to maintain the preselected spacing between adjacent vertebrae and to provide overall stability to the spinal column.

Abstract: Provided herein are antibodies that bind to a peptide of an N-terminally ubiquitinated polypeptide and methods of screening for such antibodies. Also provided herein are detection and enrichment methods using such antibodies for detecting or enriching a peptide of an N-terminally ubiquitinated polypeptide.